Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies

Blood

Volumn 102, Issue 13, 2003, Pages 4416-4423

  Siegel, Sandra ^b   Wagner, Andreas ^b   Kabelitz, Dieter ^b   Marget, Matthias ^b   Coggin Jr , Joseph ^b   Barsoum, Adel ^b   Rohrer, James ^b   Schmitz, Norbert ^b   Zeis, Matthias ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; GENE PRODUCT; HLA A ANTIGEN; HLA A2 ANTIGEN; LAMININ RECEPTOR; ONCOFETAL ANTIGEN; ONCOFETAL ANTIGEN IMMATURE LAMININ RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; BONE MARROW CELL; CELL DIFFERENTIATION; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TARGETING; GENETIC TRANSFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TARGET CELL;

EID: 0344305482     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0198     Document Type: Article

References (23)

1. Rohrer JW, Barsoum AL, Coggin JH Jr. The development of a new universal tumor rejection antigen expressed on human and rodent cancers for vaccination, prevention of cancer, and anti-tumor therapy. Mod Asp Immunobiol. 2001;5:191-195.
2. Barsoum AL, Rohrer JW, Coggin JH. 37kDa oncofetal antigen is an autoimmunogenic homologue of the 37kDa laminin receptor precursor. Cell Mol Biol Lett. 2000;19:5535-5542.
3. Castronovo V. Laminin receptors and laminin-binding proteins during tumor invasion and metastasis. Invasion Metas. 1993;13:1-30.
4. Rieger R, Edenhofer F, Lasmezas CI, Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med. 1997;12:1383-1388.
5. Rieger R, Lasmezas CI, Weiss S. Role of the 37 kDa laminin receptor precursor in the life cycle of prions. Transfus Clin Biol. 1999;6:7-16.
6. Coggin JH Jr, Barsoum, AL, Rohrer JW. Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen. Immunol Today. 1998;19:405-408.
7. Coggin JH Jr, Barsoum AL, Rohrer JW. 37 kilo-Dalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers. Anticancer Res. 1999;19,5535-5542.
8. Coggin JH Jr, Rohrer JW, Barsoum AL. A new immunological view of radiation-promoted lymphomagenesis. Int J Radiat Biol. 1997;71:81-94.
9. Rohrer JW, Barsoum AL, Dyess DL, et al. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. J Immunol. 1999;162:6880-6892.
10. Rohrer JW, Culpepper C, Barsoum AL, et al. Characterization of RFM mouse T lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, longterm survivors of sublethal X-irradiation by limiting dilution T lymphocyte cloning. J Immunol. 1995;154:2266-2280.
11. Rohrer JW, Coggin JH Jr. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol. 1995;155:5719-5727.
12. Rohrer JW, Rohrer SD, Barsoum A, Coggin JH Jr. Differential recognition of murine tumor-associated oncofetal transplantation antigen and individually specific tumor transplantation antigens by syngeneic cloned Balb/c and RFM mouse T cells. J Immunol. 1994;152:745-764.
13. Coggin JH, Rohrer SD, Leinbach ED, et al. Radiation-induced lymphoblastic lymphomas/leukemias and sarcomas of mice express conserved, immunogenic 44-kilodalton oncofetal antigen. Am J Pathol. 1988;130:136-146.
14. Zelle-Rieser C, Barsoum AL, Sallusto F, et al. Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma. J Urol. 2001;165:1705-1709.
15. Holtl L, Zelle-Rieser C, Gander H, et al. Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma. Clin Cancer Res. 2002;11:3369-3376.
16. Feuerstein B, Berger TG, Maczek C, et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods. 2000;245:15-29.
17. Su Z, Peluso MV, Raffegerst SH, Schendel DJ, Roskrow MA. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol. 2001;31:947-958.
18. Zeis M, Siegel S, Wagner A, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol. 2003;170:5391-5397.
19. Zeis M, Frenzke H, Schmitz N, et al. Idiotype protein-pulsed dendritic cells produce strong antimyeloma effects after syngeneic stem cell transplantation in mice. Bone Marrow Transplant. 2002;29:213-221.
20. Nair SK, Heiser A, Boczkowski D, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med. 2000;6:1011-1017.
21. Heiser A, Dahm P, Yancey DR, et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol. 2000;164:5508-5514.
22. Nair SK, Boczkowski D, Morse M, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998;16:364-369.
23. Coggin JH Jr. Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced Balb/c sarcomas. Mol Biother. 1989;4:223-228.